Case and source map

What the supplied questions test

Every case and lecture question that belongs to this chapter, the concept it tests, and the place in the chapter where you practise it. Lecture coverage, case coverage and original practice are labelled separately.

Case map

Source page map

Which lecture pages feed each section. Page numbers are PDF pages of the supplied files.

Sources and notes

Sources

  • L2Lesson 2 Inflammation.pdf — Inflammation and tissue repair (52 pages)
  • Ch. II casesCASES CHAPTER II.pdf (20 pages)
  • Midterm sim.Cases for simulation of midterm examination on pathology.pdf (16 pages)Mixed midterm simulation, questions numbered as in the file.
  • L1L1 Cell injury.pdf — Cell injury. Cell adaptation. Cell death (59 pages)
  • SyllabusSyllabus 1 (1).pdf — Pathology course syllabus (2 pages)Defines the midterm scope (Chapters 1–7).
  • Ref.Standard references used to verify mechanismsRobbins & Kumar Basic Pathology; Abbas Cellular and Molecular Immunology; Guyton & Hall Medical Physiology; standard toxicology texts.

Course PDFs are not served by this site. Page numbers refer to the supplied files so you can verify claims. Images labelled “Lecture image” are cropped from those files; “Teaching schematic” marks original drawings.

Source notes: where the sources differ or are ambiguous

  • LAD II. Source: “LAD-2 is a deficiency of an EC selectin that normally binds neutrophils”; clinical list (delayed cord separation, gingivitis, neutrophilia) given for both types. Taught here: LAD II is a fucosylation defect (GDP-fucose transporter): the leukocyte selectin ligand sialyl-Lewis X is missing; endothelial selectins are normal. Delayed cord separation is the LAD I clue; LAD II brings the Bombay phenotype, intellectual disability and short stature. L2 p.14
  • Endothelial integrins. Source: “venular EC expression of integrin adhesion molecules”. Taught here: Endothelium expresses integrin ligands (ICAM-1, VCAM-1); the integrins (LFA-1 = CD11a/CD18, Mac-1 = CD11b/CD18, VLA-4) are on leukocytes and are activated by chemokines. L2 p.13
  • CGD and hypochlorous acid. Source: “HOCl• (bleach)”; CGD neutrophils “will use bacterial HOCl”. Taught here: HOCl is an oxidant, not a free radical. CGD neutrophils can use H₂O₂ made by catalase-negative bacteria, which their own myeloperoxidase converts to HOCl; catalase-positive organisms destroy that H₂O₂. L2 p.20–21
  • IL-5. Source: IL-5 “enhances class type switching to IgE”. Taught here: IgE class switching is driven by IL-4 (and IL-13). IL-5 drives eosinophil production and activation and supports B-cell growth and IgA. L2 p.28
  • Angiogenesis and vasculogenesis. Source: Vessels “de novo from EC precursors recruited from the bone marrow (i.e., angiogenesis)”. Taught here: Sprouting from pre-existing vessels is angiogenesis; building vessels from marrow-derived endothelial precursors is vasculogenesis. Both contribute to repair. L2 p.48
  • Giant cells. Source: “fusion of the nuclei of epithelioid cells into one giant cell”. Taught here: Whole macrophages fuse their cytoplasm; the nuclei remain separate, which is why the cell is multinucleated. L2 p.42
  • ESR mechanism. Source: Plasma proteins (fibrinogen, immunoglobulins) “have a positive charge”. Taught here: Fibrinogen and immunoglobulins are large, asymmetric proteins that reduce the red cells' negative surface (zeta) potential and bridge them into rouleaux; they are not positively charged at blood pH. L2 p.31
  • Dysplasia as an adaptation. Source: Ch. II Q17 (= Sim Q6): “Which of the following adaptations to chronic injury…” with dysplasia as the answer. Taught here: Dysplasia is disordered growth with atypia, a possible precursor of carcinoma, not a true adaptation. Ch. II cases p.18
  • Timing in Sim Q7. Source: The Word version says the patient “expires hours later”; the PDF says 24 hours. Taught here: Neutrophils need about 12–24 hours to appear in an infarct; the PDF wording supports the keyed concept (neutrophils). Midterm sim. p.3
  • Acute-phase list in Sim Q14. Source: Ceruloplasmin and α₂-macroglobulin listed as acute-phase markers; neither is on the lecture's APR table. Taught here: Both are positive acute-phase proteins; α₂-macroglobulin rises only modestly in humans. The answer (acute-phase proteins) is unaffected. Midterm sim. p.5L2 p.29

Brief in the sources, expanded here as supporting context

  • No answer key was supplied for the Chapter II cases or the simulation; every answer was derived and checked (audit: docs/pathology-audit/chapter-2.md).
  • Triggers and sentinel cells (PAMPs, DAMPs, inflammasome) expand the lecture's one-line definition; they explain sterile inflammation in an infarct.
  • Infarct cell timelines (Ch. II Q8, Q10; Sim Q7) are not in L2; they are taught from L1 and Robbins in 2.1.
  • Exudate vs transudate criteria (specific gravity, Light criteria) are added; L2 shows only the word “exudate” on its arrival diagram.
  • LAD II, Chédiak–Higashi clinical features and MPO deficiency appear in L2 only as pictures or an enzyme label; details come from Robbins and Abbas.
  • Collateral injury by granule enzymes and the route to an abscess expand the lecture's purulent-inflammation slide.
  • Ceruloplasmin and α₂-macroglobulin come from Sim Q14, not from the lecture's acute-phase table.
  • Resolvins, protectins and efferocytosis expand the single lipoxin bullet on the termination slide; fistula is defined (the slide lists it without explanation).
  • Macrophage M1/M2 activation, the tuberculin test and IL-12/IFN-γ receptor defects are supporting context for the granuloma loop.
  • Wound-healing time course, tensile strength, collagen III → I, re-epithelialization and contracture are added from Robbins; L2 gives granulation tissue, growth factors, intention and impairing factors.
  • Cervical dysplasia (Ch. II Q17) is taught in Chapters 1 and 7; Chapter 2 practises it once in the review.